The Medical Technology Giant Where the Legal Clouds Are Lifting and the Earnings Multiple Hasn’t Caught Up

Three years of SEC headlines, infusion pump recalls, and litigation left the stock permanently filed under “do not touch.” The SEC matter is settled, the biosciences business is spun off, and adjusted EPS guidance has been raised.

Meanwhile, the core business remains intact. Overhead is lifting, but the valuation still reflects the problems the company is leaving behind.

A cleaner company than the one that got put in the penalty box

Becton, Dickinson (NYSE: BDX) completed the spin-off of its Biosciences and Diagnostic Solutions business earlier this year, combining it with Waters Corporation.

That transaction closed in February and transformed BD into a focused medical technology company operating four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional.

The most recent quarterly result showed revenue of $4.71 billion, up roughly 5% as reported. Adjusted EPS came in at $2.90, ahead of the prior year.

GAAP earnings looked far worse due to a large non-cash impairment charge the company took as part of restructuring, but that charge tells you what management is actually doing: cleaning house, aligning resources behind the highest-value platforms, and setting up the cost structure for the next phase.

Full-year adjusted EPS guidance was raised to $12.52 to $12.72, up from the prior range. That is management signaling confidence while still working through transition noise, which is a meaningful combination.

The Q4 print and FY2027 setup land in early November

BD’s fiscal year ends September 30, eight days from now. The Q4 results and the initial FY2027 framework land in early November, and that is the catalyst window.

Management already laid out a preliminary FY2027 framework on the Q3 call. November is about confirmation, not surprise. If the margin trajectory lands where they guided and FY2027 visibility is clean, the re-rating case gets specific.

The Alaris chapter is closed

The SEC investigation into BD’s Alaris infusion pump disclosures (covering a period from 2019 to 2020 when the company understated the risks of the device) was settled with a $175M civil penalty. A Fair Fund was created to distribute that penalty to affected shareholders.

That is not a small number, but it is a defined number. The tail risk of an open-ended investigation hanging over the stock is gone.

For a company doing $22 billion in annual revenue, a $175M fine is painful but survivable, and it removes the overhang that kept risk-averse institutional buyers on the sidelines.

The Bard PowerPort situation is still live

The Alaris resolution does not mean BDX is litigation-free. C.R. Bard’s implanted port catheter product is facing nearly 4,000 lawsuits consolidated in a federal MDL in Arizona.

A jury recently awarded $40M to a plaintiff in a bellwether trial on design defect and failure-to-warn claims. Additional bellwether trials are scheduled over the next several months.

This is a known and ongoing risk, not a new surprise. The key question for the thesis is whether this ends in a manageable settlement or escalates into something that materially impairs the balance sheet.

Right now, it is sized as a risk to model, not a thesis-breaker. But you need to watch the next bellwether outcomes closely.

Consumables at scale is one of the best business models in healthcare

Think about what BD actually sells. Every catheter placed in a hospital patient, every IV line started, every blood specimen collected, every syringe loaded in an automated dispensing cabinet.

These are single-use, recurring purchases driven by patient volume, not hospital capital budgets.

Over 90% of revenue is consumables. That is not an accident. BD has spent decades building a product portfolio that attaches to hospital workflows and then generates repeat purchasing indefinitely.

Switching costs aren't always contractual, but they are deep. Nurses trained on BD IV connectors do not want to re-learn a different system at 2 am.

This is razor-and-blade cash flow priced like a company with a litigation problem. The litigation problem is mostly resolved. The razor-and-blade economics are unchanged.

The Alaris recovery is an underappreciated earnings tailwind

The Alaris infusion pump, the same product at the center of the SEC case, underwent extensive remediation to restore FDA clearance. That process is largely complete.

As hospitals complete the upgrade cycle and the remediation costs roll off the P&L, you get a tailwind from both directions: lower costs and recovering revenue in a high-margin connected care segment.

Management has been signaling this transition for two quarters. It is one of the cleaner margin-expansion stories in med tech right now, and it is structural rather than cyclical.

The gap is significant, and the fundamentals do not fully explain it

Take the adjusted EPS guidance midpoint and divide it into the current price, and you get a forward multiple in the low-to-mid teens.

Stryker trades at seventeen to eighteen times forward earnings on orthopedic momentum. Medtronic sits in the mid-teens despite slower organic growth. Abbott commands a premium multiple across its diagnostics and devices portfolio.

BD has better recurring revenue characteristics than most of its peers. A consumables-heavy portfolio with deep hospital penetration is exactly the kind of business that earns premium multiples in med tech.

It is not earning that premium right now because of the litigation and restructuring drag that has clouded reported earnings.

Analyst consensus sits at 7 Buys and 7 Holds with zero Sells. The average target is approximately $196; the high end reaches $225. Both figures sit above the current price, with the stock recently trading around $180 to $181.

The gap closes not because the targets are aggressive but because the penalty-box discount on a fundamentally sound compounder should not persist once the noise clears.

The buyback adds mechanical EPS support

BD executed a $2 billion accelerated share repurchase in the most recent half, retiring $2.1 billion of debt at the same time. Share count has come down, and management has publicly committed to continued buybacks as the balance sheet strengthens.

When a $49 billion company shrinks its float while earnings recover, you get compounding EPS growth even without help from revenue acceleration.

The trailing P/E looks stretched, and it is completely misleading here.

The GAAP trailing multiple is elevated because of a $450M non-cash impairment charge taken in Q2 related to assets being exited under the “Excellence Unleashed” restructuring program.

Strip that out and look at adjusted earnings, and the forward multiple is in the low-to-mid teens, consistent with where you would expect a consumables-heavy med tech company to trade.

The important point: the impairment charge is the company removing assets that no longer earn their keep. That is not bad news dressed up as a write-down.

It is management pruning the portfolio, which is exactly what you want before a margin recovery. The companies that take restructuring pain upfront and then demonstrate clean earnings power afterward are the ones that re-rate.

Watch the adjusted operating margin trajectory, not the GAAP headline. That is where the recovery shows up first.

The Bard PowerPort litigation could get worse. The recent $40M plaintiff verdict was a meaningful data point for the thousands of remaining cases.

If the next bellwether trials produce similar outcomes and a class-wide settlement requires a materially larger reserve, that hits the balance sheet and delays the capital return story. Size this risk carefully before sizing the position.

FY2027 guidance could disappoint. Management has been telegraphing margin recovery for two quarters. If the November guide shows slower-than-expected expansion or decelerating revenue growth, the re-rating thesis stalls.

The stock has already moved significantly off its lows; there is less margin for error than a year ago.

Currency is a drag. International revenue is roughly 38% of the total, and a strong dollar clips reported results every quarter. The FX headwind has been running at approximately 200 to 300 basis points on a reported basis.

That is not a thesis-killer, but it is a mechanical headwind that depresses reported numbers relative to what the underlying business is delivering.

Debt is elevated. Total long-term debt of around $14.7B against equity of $24B is a ratio that constrains flexibility. BD is actively paying down debt, but until leverage reaches more comfortable levels, the balance sheet constrains capital-allocation optionality.

BD is a high-quality compounder that spent three years in the penalty box for valid reasons. The SEC investigation is settled. The biosciences spin-off is complete.

The Alaris recovery is underway. The restructuring charges that have distorted GAAP earnings are largely non-cash and increasingly behind the company.

What you are left with is a $49 billion medical technology business with over 90% consumables revenue, a dividend that has been raised for decades, a fresh buyback, and a forward multiple that looks cheap against every relevant peer.

The Bard PowerPort litigation is the risk that could disrupt the timing. You need to size accordingly and watch the bellwether trials over the next several months.

But this is a company where the thesis does not require anything heroic, just the absence of new bad news and the confirmation of a margin recovery the company has been promising.

Accumulate on weakness into the Q4 print, and watch the FY2027 framework that comes with it. That is your re-rating catalyst.

Looking to buy? A gradual accumulation around current levels makes sense, with the best entry points on any weakness related to the Bard litigation headlines. Do not wait for the perfect all-clear because it will not come before the stock moves.

Already own it? Hold through the early November Q4 print. The FY2027 framework is the key output. Watch adjusted operating margin and commentary on the Bard litigation reserve. Both need to be within expectations for the thesis to stay on track.

Main risk to respect: The Bard PowerPort bellwether trials over the next several months are the single biggest threat to the timeline. A large adverse verdict or an accelerated settlement could force a meaningful reserve and delay capital return to shareholders.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any value stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge